How has vascepa's price changed recently?

Why has Vascepa's price increased?

Recent price adjustments by Amarin reflect ongoing costs to maintain marketing and sales infrastructure after the FDA granted expanded approval for cardiovascular risk reduction. These updates occurred around the time of regulatory milestones in 2019–2020.

How does Vascepa compare to generic icosapent ethyl?

Generic versions entered the market after the core composition-of-matter patent expired. Generics now offer significantly lower prices than the brand, with some patients seeing savings of 70–80% when switching to an equivalent formulation.

When does Vascepa's patent expire?

Amarin continues to hold secondary patents covering specific formulations and methods of use, which extend exclusivity beyond the ursprüngliche core composition-of-matter patent. Secondary patents are under active litigation, with companies such as Hikma challenging their validity.

Why are companies challenging Vascepa's patents?

Hikma and other generic manufacturers argue that remaining patents are obvious in view of earlier fish oil studies and fish oil-related art. Litigation outcomes will determine whether additional generic launches occur before 2024 or 2025.

Can generics enter before full patent expiry?

At-risk launches remain possible if courts rule against Amarin's remaining patents. Current data show generic icosapent ethyl is already available through multiple manufacturers, providing immediate price relief for patients.

What is the current price difference between brand and generic?

Current pharmacy cash prices show Vascepa at roughly $300–400 per month compared to generic versions at $80–150 per month. The difference varies by insurance coverage and copay assistance programs.

How does Vascepa's pricing affect patient access?

Many patients rely on copay cards or patient assistance programs offered by Amarin to keep brand-name costs below $10 per month for eligible individuals. Insurance formulary decisions also determine whether generics or the brand receive preferred status.